April 23-25, 2019
Amsterdam

Speakers

Expand/Collapse

John Castle
Associate Vice President, Head of Translational Medicine & Bioinformatics
Agenus

Dr. John Castle is Associate Vice President, Head of Translational Sciences, at Agenus, Inc. Dr. Castle has deep expertise in biomarkers and therapy development using computational immunology, bioinformatics, biotechnology, and genomics. Having built translational bioinformatics and genomics units focused on immunotherapies, Dr. Castle pioneered computational approaches to identify immunogenic peptides for anti-tumor immunity. His bioinformatics approach has revolutionized Agenus’ neoantigen vaccine platform, now in Phase 1 clinical testing. Prior to joining Agenus, he served as associate director at Rosetta Inpharmatics/Merck & Co. and subsequently served as the co-director at the Biomarker Development Center of Translational Oncology at the University of Mainz, Germany. Dr. Castle was the director of bioinformatics at BioNTech AG (DE).

Day One

WEDNESDAY, 24TH APRIL 2019

12.30 | Obtaining a Fuller Picture of Immunogenicity to Improve Neoantigen Selection

12.00 | Connecting Neoantigens to TCR Recognition

Andrew Ishizuka
Chief Scientific Officer
Avidea Technologies

Andrew Ishizuka, PhD, is co-founder and CSO of Avidea Technologies. In this role, Andrew leads pre-clinical animal testing and translational studies supporting the development of Avidea’s personalized cancer vaccine technology based on self-assembling nanoparticles. Prior to joining Avidea, Andrew was a post-doctoral fellow with Dr. Robert Seder at the Vaccine Research Center, NIH. Andrew attended medical school at Duke University and has a Ph.D. from the University of Oxford.

Day Two

Thursday, 25TH APRIL 2019

15.00 | Induction of Neoantigen-specific T cells with Self-Assembling Nanoparticles

Mathias Vormehr
Head of Cancer Vaccines
BioNTech

Dr. Mathias Vormehr is an immunologist heading the research group Cancer Vaccines at BioNTech RNA Pharmaceuticals GmbH (Mainz, Germany). He holds a diploma in biomedical chemistry and a doctorate in pharmacy from the University of Mainz. His work on neoantigens and personalized cancer vaccines was published in high impact journals including Nature. Currently his research focuses on the clinical translation of cancer vaccines and the testing of suitable combination partners.

Day One

WEDNESDAY, 24TH APRIL 2019

10.00 | A Non-Functional Neoepitope Specific CD8+ T-cell Response Induced by Tumour Derived Antigen Exposure In Vivo

Michal Bassani-Sternberg
Sternberg Director, Immunopeptidomics Unit Center of Experimental Therapeutics
CHUV

Michal Bassani-Sternberg is heading the Immunopeptidomics unit that is integrated within the Center of Experimental Therapeutic (CTE) in the department of Oncology at the CHUV, Lausanne, Switzerland, where she integrates mass spectrometry based immunopeptidomics into the innovative translational clinical strategy of personalized immunotherapy. In the last ten years, Dr Bassani-Sternberg has focused her research mainly on the development of methodologies for highly accurate and in-depth immunopeptidomics. She has completed her PhD at the Faculty of Biology at the Technion - Israel Institute of Technology and post-doctorate at the Proteomics and Signal Transduction Department, headed by Prof. Matthias Mann at the Max Planck Institute of Biochemistry. Recently she has integrated next generation sequencing with immunopeptidomics to directly identify patient’s specific neo-epitopes presented on melanoma tissues.

Workshop A

TUESDAY, 23RD APRIL 2019

09.00 | Neoantigen Identification to Ensure Immunogenic & Clinically Relevant Neoantigens

Asterios Tsiftsoglou
Committee for Advanced Therapies Member
European Medicines Agency

Dr Asterios Tsiftsoglou is currently a member of Committee for Advanced Therapies at the European Medicines Agency. He is also a Professor of Pharmacology at the Department of Pharmaceutical Sciences at Aristotle University of Thessaloniki. Prior to his current position, he was Assistant Professor of Medicine (Hematology-Oncology) at Harvard Medical School. Dr Tsiftsoglou obtained his M.Sci. and PhD in Pharmacology from Yale University. and carried out Postdoctoral Research in the Center for Cancer Research at MIT, Cambridge, MA.USA

Workshop B

TUESDAY, 23RD APRIL 2019

13.00 | Regulatory Pathway & Landscape for Neoantigen-based Cancer Immunotherapy

Lélia Delamarre
Senior Scientist, Cancer Immunology Research
Genentech

Dr Delamarre is senior scientist in cancer immunology at Genentech. She joined Genentech in 2007 after her postdoctoral training at Yale University where she studied the cellular mechanisms underlying the unique capacity of dendritic cells to capture and present antigens for T cell priming. At Genentech in the Cancer Immunology Department, Dr Delamarre has been pursuing her research interests with the goal of developing novel approaches to expand effective T cell responses to cancer through priming. She has a PhD in Virology from the University of Paris

Day One

WEDNESDAY, 24TH APRIL 2019

15.00 | Determinants of Cancer Neoantigen Immunogenicity

12.30 | Obtaining a Fuller Picture of Immunogenicity to Improve Neoantigen Selection

Jessica Flechtner
Chief Scientific Officer
Genocea

Dr. Flechtner joined Genocea in 2007, soon after the company was founded, and currently serves as Chief Scientific Officer. She is widely recognized as a pioneer in the development of novel vaccines directed toward T cell immunity and has more than 20 years of experience in immunology, cancer, infectious disease, and vaccine development. She leads Genocea’s efforts to develop T cell-directed vaccines and immunotherapies against cancer using the company’s proprietary ATLAS platform to identify and characterize both common and personalized antigens. Prior to joining Genocea, Dr. Flechtner served in a variety of roles developing vaccines and immunotherapies for cancer, infectious disease, autoimmunity, and allergy at companies including Mojave Therapeutics and Antigenics (now Agenus). She received a B.S. in Animal Science and a Ph.D. in Cellular Immunology from Cornell University, and performed her post-doctoral work at Dana Farber Cancer Institute and Harvard Medical School. Dr. Flechtner is a member of Women in Bio, the American Association of Immunologists, American Association for Cancer Research, Society for Immunotherapy of Cancer, President’s Council of Cornell Women, and American Society for Microbiology. She is also an inventor on numerous pending and issued patents and is the author of multiple peer-reviewed scientific publications.

Day Two

Thursday, 25TH APRIL 2019

14.00 | Panel Discussion: Global Clinical Development of Neoantigen-based Cancer Therapies

10.30 | Beyond Algorithms: The ATLAS Bioassay Method for Neoantigen Identification & Characterization

Jennifer Busby
Senior Director of Mass Spectrometry & Proteomics
Gritstone Oncology

Dr. Jennifer (Caldwell) Busby is a Senior Director and manages Gritstone Oncology’s Proteomics efforts. The combined data from the Sequencing and Bioinformatics teams has resulted in the EDGE prediction model developed by Gritstone to predict presentation on the tumor surface of therapeutically relevant peptides. Dr. Busby received her PhD from the lab of Dr. Don Hunt at the University of Virginia and throughout her career has worked with high resolution mass spectrometry data to provide insight into variety of biological systems including epigenetics and immunology. She has held previous positions at Constellation Pharmaceuticals, Scripps Florida and OPKO Health.

Day One

WEDNESDAY, 24TH APRIL 2019

12.30 | Obtaining a Fuller Picture of Immunogenicity to Improve Neoantigen Selection

09.30 | Neoantigen Prediction: Approach & Validation

Norbert Hilf
Director of Translational Development
Immatics

Norbert Hilf, Ph.D., is Vice President Translational Development of Immatics biotechnologies GmbH, a biotech company located in Germany and Texas dedicated to developing T-cell based immunotherapies against cancer. Dr. Hilf studied biochemistry, having received his doctoral degree in Biochemistry / Immunology from the University of Tuebingen, Germany working in the Department of Immunology headed by Hans-Georg Rammensee.

Dr. Hilf joined Immatics biotechnologies in 2004. Dr. Hilf’s department focuses on the translation of Immatics’ treatment modalities into early phase clinical development, including adoptive cellular therapies, bispecific T-cell receptors, and personalized vaccine approaches.

Day Two

Thursday, 25TH APRIL 2019

10.00 | Integrating Non-Mutated and Neoantigens into Highly Personalised Immunotherapy Approaches – Clinical Experiences

John Wang
Chief Executive Officer
IOVaxis

Dr. John Wang is the founder and CEO of IOVaxis Therapeutics Inc ( since its inception in 2012. The company has a mission to develop personalised therapeutic cancer vaccines. Before forming IOVaxis, Dr. Wang had worked for over 25 years at Novartis, Chiron in US and Mimotopes in Australia with increasing responsibility and had worked on both small molecule, protein drug and vaccine projects. During his work, he had participated in various international collaborations including those in Singapore, Japan, Russia and Korea, as well as leading Chinese pharmaceutical companies. Dr. Wang was graduated from China Pharmaceutical University at Nanjing, China and PhD in Pharmacology from the “Mario Negri Institute for Pharmacological Research” at Milano, Italy. He conducted his post-doc work at University of Arizona under the late Professor Emeritus, Dr. Hank Yamamura. Dr. Wang was a visiting Professor of China Pharmaceutical University and the Research Institute of Pharmacology and Toxicology, MMA.

Day Two

Thursday, 25TH APRIL 2019

14.00 | Panel Discussion: Global Clinical Development of Neoantigen-based Cancer Therapies

Trevor Clancy
Chief Scientific Officer
OncoImmunity

Dr. Clancy has a PhD degree in cancer bioinformatics from the University of Oslo. He has an immunological background developing computational immune-profiling methods, in several national and international cancer related projects. Dr. Clancy has more than 12 years experience in bioinformatics and 7 years of commercial experience in bioinformatics product development. He has an active scientific profile in applying immune informatics for biomarker discovery in cancer.

Day One

WEDNESDAY, 24TH APRIL 2019

10.30 | An Integrated Machine-Learning Approach to Improve the Prediction of Clinically Relevant Neoantigens

Sean Boyle
Director, Bioinformatics Applications
Personalis

Sean is Director of Bioinformatics Applications at Personalis, with broad experience across analysis and interpretation of cancer genomics data.  At Personalis, Sean leads a team focused on development neoantigen prediction, cell free applications, tumor microenvironment analysis, and biomarker analysis for the ACE ImmunoID platform.   His team is also applying these technologies through external scientific collaborations with both academic and industry partners. Prior to Personalis, Sean worked on advancing genomics and personalized genomic medicine, notably with the Dr. Mike Snyder lab at Stanford University, where he developed novel methods for analyzing and interpreting patient samples from both cancer and inherited disease.

Day One

WEDNESDAY, 24TH APRIL 2019

14.30 | ImmunoID NeXT Platform: Improving Neoantigen Prediction, TME Assessment, & ctDNA Detection for Vaccine Development

Agnete Fredriksen
Chief Scientific Officer
Vaccibody

Agnete B. Fredriksen is Founder and Chief Scientific Officer of Vaccibody AS. She holds a M.Sc., Ph.D. from Institute of Immunology, University of Oslo, Rikshospitalet in Norway where she designed and developed the first Vaccibody vaccines. Agnete is one of the inventors of the Vaccibody technology and received the King’s Gold Medal for her PhD thesis on Vaccibodies. She has co-authored a range of scientific papers and is inventor on several patents with a focus on vaccine development and immunotherapy. She is in charge of the preclinical development of neoantigen-based vaccines at Vaccibody aiming for first clinical trials in 2017.

Day Two

Thursday, 25TH APRIL 2019

14.00 | Panel Discussion: Global Clinical Development of Neoantigen-based Cancer Therapies

12.00 | Bringing Individualised Neoantigen-based Cancer Vaccines into the Clinic; Challenges, Learnings & Victories

Laurence Cooper
Chief Executive Officer
Ziopharm

Laurence Cooper M.D., Ph.D., serves as Chief Executive Officer of Ziopharm Oncology and maintains a position as a Visiting Scientist at MD Anderson Cancer Center (MDACC) and is a board-certified physician in pediatric oncologist. Dr. Cooper joined Ziopharm in 2015 to develop gene and cell immunotherapies. One of the programs delivers TCR-modified T cells targeting neoantigens in solid tumors. Prior to his appointment in industry, Dr. Cooper was a tenured professor in the Division of Pediatrics and Department of Immunology. At MDACC, he led the bone marrow transplantation program and scientific efforts to develop and implement new treatment approaches that pair genetic engineering with immunotherapies.

Day Two

Thursday, 25TH APRIL 2019

09.30 | One for All & All for One – Bioengineering of T cells with Specificity for Neoantigens in Solid Tumours